834
Bennett, C.N. and Horrobin, D.F. Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update [review]
Prostaglandins Leukot Essent Fatty Acids 2000; 63(1): 47-59. (Abstract)
835
Ho, L.; Pasinetti, G.M.; Horrocks, L.A.; Faroqui, A.A.; Horrobin, D.F.; Peet, M.; Manev, H. Eicosanoid pathways in psychiatric disorders (Abstract)
Biol Psychiatry 2000; 47: 114S.
836
Horrobin, D.F. Essential fatty acid metabolism and its modification in atopic eczema [review]
Am J Clin Nutr 2000; 71(1 Supp): 367S-72S. (Full text)(Abstract)
837
Horrobin, D.F. Why is speculation so awful? [letter]
Br Med J 2000; 321(7260): 571-2. (Full text)
838
Horrobin, D.F. Photodynamic injury from Foscan [letter]
Br Med J eletters: http://bmj.com/cgi/eletters/321/7252/53/a#11234 2000. (Full text)
839
Horrobin, D.F. A revolution in drug discovery [letter]
Br Med J eletters: http://bmj.com/cgi/eletters/321/7261/581#9991 2000. (Full text)
840
Horrobin, D.F. Low frequency EMF, visible light, melatonin and cancer [Conference report]
In: Erren TC, Piekarski C. (Eds.) Low frequency EMF, visible light, melatonin and cancer - International symposium May 4-5, 2000 University of Cologne. Zbl Arbeitsmed 2000; 50: 298-314. (Full text)
842
Horrobin, D.F. The other side of Scotia's drug policy
Investor's Chronicle 2000; 134: 120.
843
Horrobin, D.F. Innovation in the pharmaceutical industry
J R Soc Med 2000; 93(7): 341-5. (Full text)
844
Horrobin, D.F. The LAX-101 research project in Huntington's disease
Presentation to: Huntingdon Disease Association Conference, Sheffield, UK. 21 October 2000. (Full text)
845
Horrobin, D.F. Commentary on the workshop statement: are we really sure that arachidonic acid and linoleic acid are bad things?
Prostaglandins Leukot Essent Fatty Acids 2000; 63(3): 145-7.
846
Horrobin, D.F. Phospholipid metabolism and perinatal events whiche lead to increased risk of schizophrenia
Schizophrenia Res 2000; 41: 250.
847
Horrobin, D.F. Interactions between cannabinoids and phospholipid metabolism in schizophrenia
Schizophrenia Res 2000; 41: 250.
848
Horrobin, D.F. Phospholipid metabolism and pregnancy-related events which enhance risk of schizophrenia
Schizophrenia Res 2000; 41: 251.
849
Horrobin, D.F. Phospholipases as candidate genes in schizophrenia
Schizophrenia Res 2000; 41: 98.
850
Horrobin, D.F. and Bennett, C.N. Fatty acid coenzyme A ligases as candidate genes in schizophrenia
Schizophrenia Res 2000; 41: 99.
851
MacDonald, D.J.; Glen, A.C.A.; Boyle, R.M.; Glen, A.I.M.; Ward, P.; Horrobin, D.F. An ELISA method for type IV cPLA2 in RBC: a potential marker for schizophrenia
Schizophrenia Res 2000; 41: 259.
853
MacDonnell, L.E.F.; Skinner, F.K.; Ward, P.E.; Glen, A.I.M.; Glen, A.C.A.; MacDonald, D.J.; Boyle, R.M.; Horrobin, D.F. Type IV cPLA2 in red blood cells: evidence for differences between two subgroups on dyslexic-type adults and controls
Schizophrenia Res 2000; 41: 258.
854
Martin, D.S.D.; Towey, M.; Horrobin, D.F.; Lynch, M.A. A diet enriched with alpha-lipoic acid reverses the age-related compromise in antioxidant defences in rat cortical tissue
Nutr Neurosci 2000; 3: 193-206.
855
Peet, M.; Glen, A.I.M.; Ward, P.; Rowlands, P.; Puri, B.K.; Murray, R.; de Wet, C.; Kendall, K.; Abed, R.; Inch, H.; Driscoll, P.; Lloyd, G.; Barber, M.; Hay, A.; McGregor, A.; Hellewell, J.; Mackenzie, A.; Glen, F.; Horrobin, D.F. Effects of eicosapentaenoic acid in schizophrenia: a placebo-controlled trial (Abstract)
Presented at: 10th Winter Workshop on Schizophrenia, Davos, Switzerland, February 2000.
856
Peet, M.; Horrobin, D.F.; Glen, A.I.M.; Ward, P.; Rowlands, P.; Puri, B.K.; Murray, R.; de Wet, C.; Kendall, K.; Abed, R.; Inch, H.; Driscoll, P.; Lloyd, G.; Barber, M.; Hay, A.; McGregor, A.; Hellewell, J.; Mackenzie, A.; Glen, F. Eicosapentaenoic acid in the management of treatment-unresponsive schizophrenia (Abstract)
Presented at: Br Assoc Psychopharmacol Summer Meeting, 16-19 July, Cambridge, UK. 2000: 43.
857
Puri, B.K.; Richardson, A.J.; Easton, T.; Saeed, N.; Counsell, S.J.; Hajnal, J.V.; Bydder, G.M.; Horrobin, D.F. Reduced neuronal membrane phospholipid turnover and normalization of blood fatty acids associated with symptom remission in a patient with schizophrenia treated solely with eicosapentaenoic acid
Schizophr Res 2000; 41: 243.
858
Puri, B.K.; Richardson, A.J.; Horrobin, D.F.; Easton, T.; Saeed, N.; Oatridge, A.; Hajnal, J.V.; Bydder, G.M. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes
Int J Clin Pract 2000; 54(1): 57-63. (Abstract)
859
Ward, P.E.; Glen, A.I.M.; Glen, A.C.A.; MacDonald, D.J.; Boyle, R.M.; Horrobin, D.F. Phospholipids, niacin skin test and type IV cPLA2 in schizophrenia
Schizophr Res 2000; 41: 244.
860
Ward, P.E.; Glen, A.I.M.; MacDonald, D.J.; Boyle, R.M.; Horrobin, D.F. Type IV cPLA2 in red blood cells: a preliminary clinical evaluation of its use as a marker for schizophrenia
Schizophr Res 2000; 41: 259.